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Objective: Type 2 diabetes mellitus (T2DM) is associated with subclinical myocardial injury although the underlying
mechanism is uncertain. We postulated that arterial stiffness, endothelial dysfunction and subclinical atherosclerosis
may contribute to subclinical myocardial injury in patients with T2DM.
Methods: Serum high-sensitivity troponin I (hs-TNI) an indicator of myocardial injury, was measured in 100 patients
with T2DM without clinical evidence of macrovascular disease and 150 age and gender-matched controls. Elevated
hs-TnI was defined as follow (derived from the 99th percentile from controls): Male >11.1 ng/L; female >7.6 ng/L.
Measures that may contribute to myocardial damage in patients with T2DM, including brachial-ankle pulse wave
velocity (ba-PWV), brachial flow mediated dilatation (FMD) and carotid intima media thickness (IMT), were also
assessed.
Results: The serum level of hs-TNI (5.7±9.2 μg/L vs. 3.2±1.9 μg/L, P< 0.01) and the prevalence of elevated hs-TNI
(12% vs. 4%, P = 0.02) were significantly higher in patients with T2DM than controls. Patients with T2DM also had
significantly worse ba-PWV (17.98±3.91ms-1 vs. 15.70±2.96 ms-1), brachial FMD (2.6±3.5% vs. 5.5±4.2%, P< 0.01) and
carotid IMT (0.96±0.20 mm vs. 0.86±0.14 mm, P< 0.01). In patients with T2DM, hs-TNI was positively correlated with
systolic blood pressure (r = 0.31, P<0.01), serum creatinine (r = 0.26, P = 0.01) and ba-PWV (r = 0.34, P< 0.01).
Importantly, multiple regression revealed that only ba-PWV was independently associated with hs-TNI
(β = 0.25, P = 0.04).
Conclusion: The results demonstrated an independent association between ba-PWV and hs-TNI in patients with
T2DM with no clinical evidence of macrovascular disease. These findings suggest that increased arterial stiffness is
closely related to subclinical myocardial injury in patients with T2DM.
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Patients with type 2 diabetes mellitus (T2DM) have up
to a two-fold increased risk of cardiovascular morbidity
and mortality [1,2]. As well as the close association
with coronary artery disease, hyperglycemia can cause
myocardial injury [3] and dysfunction [4], independent
of underlying macrovascular disease.* Correspondence: khkyiu@hotmail.com; hftse@hkucc.hku.hk
1Division of Cardiology, Department of Medicine, the University of
Hong Kong, Rm 1929b, Block K, Queen Mary Hospital, Hong Kong, China
2Research Centre of Heart, Brain, Hormone and Healthy Aging, Li Ka Shing
Faculty of Medicine, the University of Hong Kong, Hong Kong, China
© 2013 Yiu et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orWhile sophisticated cardiovascular imaging, such as
cardiac magnetic resonance imaging, may detect sub-
clinical myocardial injury, its clinical application is lim-
ited by its high cost and the need for a prolonged study
time. Emerging biomarkers may provide an alternative
means to non-invasively detect myocardial damage.
High-sensitivity cardiac troponin levels, a novel marker
that allows detection of troponin below clinical thresh-
olds, has been shown to predict cardiovascular events in
patients with T2DM [5], congestive heart failure [6] and
the general population [7,8]. In addition to its prognostic
value, high-sensitivity troponin can be used to detect. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with no overt macrovascular disease [3]. The underlying
pathology of this subclinical myocardial injury in pa-
tients with T2DM has nonetheless not been evaluated.
Increased arterial stiffness has been recently shown to
be related to myocardial damage in the general popula-
tion [9]. Endothelial dysfunction [10] and subclinical
atherosclerosis [11] may also contribute to subclinical
myocardial damage. Thus the objective of this study
was to determine whether arterial stiffness evaluated by
brachial-arterial pulse wave velocity (ba-PWV), endo-
thelial dysfunction measured by brachial flow mediated
dilatation (FMD) and atherosclerotic burden assessed
by carotid intima media thickness (IMT) are related to
the myocardial injury, as indicated by high sensitivity
troponin level, in patients with T2DM.
Methods
Consecutive T2DM patients as defined by World Health
Organization criteria on stable hypoglycemic and cardio-
vascular medication for at least 3 months were recruited
from the medical outpatient clinic. Exclusion criteria
included poorly controlled diabetes (hemoglobin A1c
(HbA1c) ≥11%], dilated cardiomyopathy, significant val-
vular heart disease, chronic atrial fibrillation, New York
Heart Association class III/IV heart failure, creatinine
level greater than 220 mmol/liter, documented history of
acute coronary syndrome, stroke, coronary revasculari-
zation and refusal to participate. The total of number of
T2DM patients was 100. During the study period, 150
age- and sex-matched Chinese controls without T2DM,
established cardiovascular disease or chronic inflamma-
tory disease were recruited from a community health
screening programme. Written informed consent was
obtained from all study subjects. The study was ap-
proved by the local institutional review board and was
conducted according to the Declaration of Helsinki.
Clinical parameters
Baseline demographic data, clinical characteristics, blood
sampling, ba-PWV, brachial FMD and carotid IMT were
obtained on the same day in all study subjects. Blood
pressure, body weight, body height, and body mass index
(BMI) were also measured. Hypertension was defined as
resting systolic or diastolic blood pressure >140 mmHg
or >90 mm Hg, respectively, at two different clinic
visits or the prescription of antihypertensive medica-
tion. Hypercholesterolemia was defined as fasting total
plasma cholesterol ≥4.9 mmol/liter or the prescription
of statins. Smoking status was recorded as ever smoker
(past or current) or nonsmoker.
Serum HbA1c, total cholesterol, triglyceride, high-
density lipoprotein cholesterol and low-density lipopro-
tein cholesterol levels, fasting glucose, HbA1c and highsensitivity C-reactive protein (hs-CRP) were measured in
all subjects in a fasting venous blood sample [12]. The
new serum level of high sensitivity troponin I (hs-TnI)
was determined using Chemoluminescent Microparticule
ImmunoAssay (Architect i1000SR Abbott®, Paris, France).
The level of detection is 1.2 ng/L according to the manu-
facturer’s instruction and above such is considered to be a
detectable hs-TnI. Prior studies demonstrated that the
99th percentile of hs-TnI assays varies across different
study groups [13,14]. Accordingly, the present study de-
fined the 99th percentile based on the hs-TnI of an age-
matched healthy control for both genders, respectively.
Detailed protocols for cardiovascular assessment have
been previously described: (1) arterial stiffness assessed
by ba-PWV (VP-2000 system; Colin Corp., San Antonio,
TX, U.S.A.) [12], (2) vascular endothelial function mea-
sured as flow-mediated dilatation (FMD) of the brachial
artery with a high-resolution ultrasound system (Agilent
Sonons 5500; Philips, Andover, MA) [15] and, (3) carotid
atherosclerosis measured as carotid IMT using a high-
resolution ultrasound system (Agilent Sonons 5500;
Philips, Andover, MA) [16].
Statistical analysis
Data are expressed as mean ± standard deviation for
continuous variables and frequencies or proportions for
categorical variables. Continuous demographic variables
of the two groups were compared using the Mann-
Whitney U test and categorical demographic variables
compared using Pearson Chi-square test or the Fisher’s
exact test if at least one cell had an expected cell count
below five. In order to detect factors associated with
subclinical myocardial damage in patients with T2DM,
multivariate analyses for ba-PWV, brachial FMD and
carotid IMT were performed with an enter linear regres-
sion model in which each variable with P< 0.10 (according
to the univariate analysis) was chosen.
All statistical analyses were performed using the stat-
istical package SPSS for windows (Version 18.0, SPSS,
Chicago, USA). All P values reported are 2-sided for
consistency. A P value < 0.05 was considered statisti-
cally significant.
Results
Clinical characteristics
Clinical characteristics, blood tests and cardiovascular
assessment of study patients is shown in Table 1. The
mean duration of disease for patients with T2DM was
10.5±7.8 years and 18 (18%) were maintained on insulin
therapy. Patients with T2DM had a higher systolic blood
pressure, BMI, serum creatinine, fasting blood glucose,
HbA1c and a lower high density lipoprotein than con-
trols. The prevalence of hypertension and hypercholes-
terolemia was also higher in patients with T2DM.
Table 1 Clinical characteristics, blood tests and
cardiovascular assessment of patients with type 2
diabetes mellitus (T2DM) and controls
Parameters T2DM Controls P
value(n = 100) (n = 150)
Age, years 62±10 60±9 0.20
Female, % (n) 53 (53) 51(77) 0.90
Systolic blood pressure, mmHg 138±19 121±19 <0.01
Diastolic blood pressure, mmHg 77±9 74±9 0.01
Body mass index, kg/m2 25.5±4.2 23.5±3.4 <0.01
Medical history
Current smoker, % (n) 26 (26) 18 (27) 0.16
Hypertension, % (n) 61 (61) 11 (17) <0.01
Hypercholesterolemia, % (n) 60 (60) 27 (40) <0.01
Serum lipid profile, renal function and inflammatory marker
Total cholesterol, mmol/L 4.9±0.9 5.1±0.8 0.15
Triglycerides, mmol/L 1.5±0.8 1.3±0.7 0.03
High density lipoprotein, mmol/L 1.4±0.4 1.5±0.4 <0.01
Low density lipoprotein, mmol/L 2.8±0.7 3.0±0.7 0.10
Creatinine, μmol/l 80±23 75±15 0.03
Fasting glucose, mmol/L 7.4±2.1 5.0±0.5 <0.01
HbA1c, % 7.6±1.2 5.9±0.4 <0.01
hs-CRP, mg/L 2.3±5.3 2.3±5.2 0.98
hs-TnI, μg/L 5.7±9.2 3.2±1.9 <0.01
Elevated hs-TnI, %(n) 10 (10) 1 (1) <0.01
Cardiovascular assessment
ba-PWV, ms-1 17.98±3.91 15.70±2.96 <0.01
Brachial FMD, % 2.6±3.5 5.5±4.2 <0.01
Carotid IMT, mm 0.96±0.20 0.86±0.14 <0.01
Abbreviations: ba-PWV brachial ankle pulse wave velocity, FMD flow mediated
dilatation, hs-CRP high sensitivity C-reactive protein, hs-TnI high sensitivity
Troponin I, IMT intima media thickness.
Table 2 Correlation of high-sensitivity Troponin I (hs-TnI)
with clinical variables in patients with type 2 diabetes
mellitus
Clinical variables hs-TnI
r P value
Age 0.08 0.46
Body mass index 0.15 0.14
Systolic blood pressure 0.31 <0.01
Diastolic blood pressure 0.12 0.26
Total cholesterol 0.05 0.66
Triglyceride 0.02 0.87
High density lipoprotein 0.05 0.60
Low density lipoprotein 0.01 0.91
Creatinine 0.26 0.01
Fasting Glucose 0.19 0.11
HbA1c 0.09 0.39
hs-CRP 0.11 0.29
Duration of disease 0.13 0.21
Abbreviations as in Table 1.
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The serum level of hs-TnI, representing the degree of
myocardial injury, was significantly higher in patients
with T2DM (Table 1). The concentration of hs-TnI was
at or above the limit of detection in 246 patients (97%).
In this study, the 99th percentile value of serum hs-
TnI level in male and female control subjects was 11.1
ng/L and 7.6 ng/L, respectively. These serum levels were
defined as the cut-off values for elevated serum hs-TnI.
Based on these cut-off values, patients with T2DM had a
higher prevalence of elevated serum hs-TnI level than
control (10% vs. 1.4%, P< 0.01).
For the whole study population, those with elevated hs-
TnI were more likely to have T2DM, hypertension and a
higher systolic blood pressure, creatinine and HbA1c level.
Following adjustment for age, gender, T2DM, smoking
history, hypertension and hypercholesterolemia, T2DM(OR = 3.44, CI = 1.03 – 12.00, P = 0.04) remained inde-
pendently associated with elevated hs-TnI.
High-sensitivity Troponin I in patients with T2DM
Correlation of hs-TnI with clinical parameters in patients
with T2DM is shown in Table 2. Serum level of hs-TnI
was positively correlated with systolic blood pressure and
serum creatinine, but not hs-CRP or duration of disease.
A linear correlation of hs-TnI with cardiovascular markers
in patients with T2DM is shown in Figures 1, 2, 3. The
serum level of hs-TnI was positively correlated with ba-
PWV, but not with brachial FMD or carotid IMT.
Multivariate analysis for predictors of elevated hs-TnI in
patients with T2DM
Multivariate analysis was performed to detect factors
independently associated with myocardial injury mea-
sured by hs-TnI. Univariate analysis demonstrated that
systolic blood pressure, serum creatinine and ba-PWV
were significantly related with hs-TnI. Multivariate ana-
lysis revealed that only ba-PWV remained associated
with elevated hs-TnI in patients with T2DM (Table 3).
Discussion
The present study demonstrated that patients with
T2DM have subclinical myocardial injury as detected by
elevated levels of hs-TnI. Arterial stiffness evaluated by
ba-PWV was the only parameter associated with hs-TnI
in patients with T2DM.
Previous studies have consistently demonstrated that
subclinical myocardial necrosis detected by troponin I
predicted adverse cardiovascular events in patients with
Figure 3 Correlation of atherosclerosis measured by carotid
intima-media thickness (IMT) with high-sensitivity Troponin I.
Figure 1 Correlation of arterial stiffness measured by
brachial-ankle pulse wave velocity (ba-PWV) with
high-sensitivity Troponin I.
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future adverse cardiovascular events, the use of a high-
sensitivity assay permits detection of minimally elevated
troponin that represents subclinical myocardial damage
[3,7,19,20]. In a recent report from the Atherosclerosis
Risk in Communities (ARIC) study (n = 9661), subclin-
ical myocardial injury, detected by high-sensitivity tropo-
nin T, was closely associated with hyperglycemia in
patients with no history of atherosclerotic disease [3].
Similarly, this study demonstrates that patients with
T2DM and no clinically relevant atherosclerotic disease
had myocardial damage detected by hs-TnI. This sug-
gests that T2DM contributes to subclinical myocardial
injury, independent of clinically overt atherosclerotic
disease.
Arterial stiffness measured by PWV (carotid to femoral)
is a strong predictor for adverse cardiovascular events in
community-based subjects [21]. Studies have also demon-
strated that T2DM is associated with increased arterialFigure 2 Correlation of endothelial function measured brachial
flow-mediated dilatation (FMD) with high-sensitivity Troponin I.stiffness that may partly explain the increased cardio-
vascular risk [22]. Although arterial stiffness has been
postulated to act as a surrogate marker for underlying
atherosclerosis and reflect clustering of cardiovascular
risk factors, the exact mechanism of how this correlates
with adverse cardiovascular outcome is uncertain. Studies
have previously demonstrated that PWV was related
with left ventricular diastolic dysfunction detected by
echocardiography [23,24]. Further, a recent report dem-
onstrated that increased ba-PWV was associated with
high-sensitivity troponin T level in a community-based
subject aged over 60 (T2DM in 26%) [9]. This suggests
that arterial stiffening may cause subclinical myocardial
injury, resulting in adverse cardiovascular events. The
present study further demonstrated that arterial stiff-
ness measured by ba-PWV was independently associ-
ated with elevated hs-TnI in patients with T2DM. The
current results therefore suggest that increased arterial
stiffness is related to subclinical myocardial injury and
contribute to an adverse cardiovascular outcome in pa-
tients with T2DM.
Patients with T2DM have increased arterial stiffness due
to multiple mechanisms including increased oxidative
stress [25], accelerated endothelial cell apoptosis [26],
endothelial dysfunction [27] and depletion of endothelial
progenitor cells [28]. Arterial stiffening may subsequently
cause myocardial damage in several ways although the
exact mechanism is uncertain. Decreased compliance of
the aorta increases systolic pressure and left ventricular
preload, resulting in elevated stress on the left ventricular
myocardium during the systolic phase. This may predis-
pose patients to develop left ventricular hypertrophy that
is associated with an elevated high-sensitivity troponin
level [7]. Further, a reduction in diastolic pressure de-
creases coronary perfusion that may lead to myocardial
ischemia, independent of underlying coronary atheroscler-
otic burden [29]. Finally, increased arterial stiffness may
Table 3 Predictors for high-sensitivity troponin I in patients with type 2 diabetes mellitus
Univariate analysis Multivariate analysis
Variables β 95% CI P value β 95% CI P value
Age 0.08 −0.11 – 0.25 0.46
Female Sex 0.17 −0.50 – 6.73 0.09 0.16 −1.45 – 7.44 0.18
Systolic blood pressure 0.31 0.05 – 0.24 <0.01 0.17 −0.03 – 0.19 0.16
Diastolic blood pressure 0.12 −0.10 – 0.34 0.26
Body mass index 0.15 −0.11 – 0.76 0.14
Current smoker −0.03 −4.76 – 3.59 0.78
Hypertension 0.16 −0.66 – 6.75 0.11
Duration of disease 0.13 −0.04 – 0.20 0.21
Total Cholesterol 0.05 −1.63 – 2.56 0.66
Triglyceride 0.02 −2.03 – 2.41 0.87
High density lipoprotein 0.05 −3.77 – 6.55 0.60
Low density lipoprotein 0.01 −2.35 – 2.64 0.91
Serum creatinine 0.26 0.02 – 0.18 0.01 0.05 −0.08 – 0.12 0.66
Fasting glucose 0.19 −0.16 – 1.92 0.11
HbA1c 0.09 −0.83 – 2.14 0.39
hs-CRP 0.11 −0.17 – 0.54 0.29
ba-PWV, ms-1 0.34 0.30 – 1.24 <0.01 0.25 0.04 – 1.18 0.04
Brachial FMD, % 0.10 −0.27 – 0.78 0.33
Carotid IMT, mm 0.11 −3.96 – 14.04 0.27
Abbreviations as in Table 1.
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tering of adverse cardiovascular risk profiles and systemic
inflammation. Nonetheless the means by which arterial
stiffening relates to myocardial injury in patients with
T2DM requires evaluation by further prospective study.
A number of further mechanisms have also been pro-
posed to contribute to myocardial injury in patients with
T2DM. The present study thus sought to identify any such
additional mechanisms. Hyperglycaemia may induce im-
paired brachial FMD [30], which represents an early stage
of atherosclerosis. Further, carotid IMT, a well validated
surrogate for subclinical atherosclerosis, has been shown
to be increased in patients with T2DM and its progression
can be slowed by intensive treatment [31]. The current
study nonetheless demonstrated that only ba-PWV, not
brachial FMD or carotid IMT, correlated with hs-TnI. A
previous population-based study likewise was unable
to demonstrate an association between elevated high-
sensitivity troponin T level and atherosclerosis evaluated
by coronary calcification [7]. These findings thus suggest
that troponin release in chronic setting differs from those
in acute setting, and is not associated with subclinical ath-
erosclerosis measured by brachial FMD and carotid IMT.
Limitations
The present study had several limitations. A causal rela-
tionship between arterial stiffness and myocardial injurycould not be established because of the cross-sectional
nature of the study. Although patients with T2DM were
all clinically free from overt cardiovascular complica-
tions, silent coronary artery disease could not be exclu-
ded. Further, this study did not replicate the previously
demonstrated association of hs-TnI with hbA1c% [3],
likely due to the small study population. The possibility
of residual confounding factors could not be excluded
even though the results were adjusted for multivariate
covariates. The use of direct assessment of atheroscler-
osis, such as coronary angiography or coronary endothe-
lial function assessment using intracoronary acetylcholine
infusion may provide addition information regarding the
relation between atherosclerosis and hs-TnI. However,
these tests are invasive in nature and therefore may not be
clinically feasible to perform for research purpose. More-
over, whether advanced glycation end products, an inter-
mediate product that is elevated in patients with T2DM
and an independent marker of post-infarction heart fail-
ure, would contribute to elevation of hs-TnI would require
evaluation by future studies [32].
Conclusion
The present study demonstrated that in patients with
T2DM and no clinical evidence of macrovascular disease,
ba-PWV was independently associated with hs-TnI. Bra-
chial FMD and carotid IMT showed no such association.
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tributes to subclinical myocardial injury in patients with
T2DM, beyond the development of clinically relevant ath-
erosclerotic disease.
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